Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK0869 in Major Depressive Disorder
NCT00042029Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2002
- Primary completion
- Oct 2003
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing MK0869 with Placebo (2 arms). Primary endpoints: Hamilton Depression Rating Scale 17-Item and Tolerability. Started Jun 2002; status: completed.
02
Drugs
aprepitant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00042029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00042029.